Company overview
PlaqueTec is a precision medicine company pioneering biomarker-based strategies for coronary artery disease (CAD), the leading cause of death worldwide. The company has developed the Liquid Biopsy System (LBS), a specialized catheter that collects blood samples containing biomolecules from coronary plaque at multiple sites simultaneously. PlaqueTec collaborates with research institutions and drug discovery partners to identify endotype-specific biomarkers and advance personalized treatment approaches for CAD.
Plaquetec is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include coronary artery disease, liquid biopsy, precision medicine, biomarkers, cardiovascular.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.plaquetec.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- coronary artery disease, liquid biopsy, precision medicine, biomarkers, cardiovascular
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is the PlaqueTec Liquid Biopsy System and how does it work?
- The PlaqueTec Liquid Biopsy System (LBS) is a specialized catheter designed to quickly and reliably collect blood samples containing biomolecules localizing at or being released by coronary plaque. The system samples from the boundary layer at four sites simultaneously, enabling detection of predictive intracoronary artery biomarkers.
- What therapeutic area does PlaqueTec focus on?
- PlaqueTec focuses exclusively on coronary artery disease (CAD), developing precision medicine strategies for prevention, diagnosis, and treatment. The company is dedicated to advancing the understanding of CAD through biomarker identification and endotyping approaches.
- What collaborations has PlaqueTec established?
- PlaqueTec has collaborated with the Babraham Institute on blood screening and flow cytometry analysis to improve CAD treatment, and with RxCelerate on early-phase drug discovery to assess small molecules targeting PlaqueTec-identified biomarkers in cell-based assays.
Related editorial coverage
- STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
- Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
- Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
- Bio-IT World Conference: Oncology Highlights - Day 1
- BioMed Israel 2024: Key Innovations and US Partnerships
- ISPOR 2026: Top Cardiology Innovations & Research Highlights
Explore lab tools and QA/QC resources for R&D teams.
